Foxo6 – A Novel Target for Parkinson’s Disease

Desai, Shivani; Pansare, Prajakta; Sainani, Shivani; Doke, Rohit R; Bhalchim, Vrushali; Rode, Ketki

doi:10.13005/bpj/1897

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of alpha-synuclein, a protein associated with the disease, is significantly increased throughout the brain in PD and is considered a significant biomarker. 25,26 To address the management of PD, researchers have developed a novel biodegradable nanoparticle composed of Polyethylene Glycolpolylactide-Polyglycolide (PEG-PLGA) loaded with lactoferrin. This nanoparticle formulation aims to facilitate the accumulation of lactoferrin in the brain and improve central nervous system drug delivery in PD models.…”

Section: Parkinson's Disease (Pd)mentioning

confidence: 99%

Recent advances in nanotherapeutics for epilepsy and neurodegenerative diseases

Kuchik,

Doke,

Bhor

et al. 2023

JPBS

View full text Add to dashboard Cite

This review focuses on the potential of nanotherapeutics in the diagnosis and treatment of neuronal abnormal conditions particularly epilepsy, alzheimer's disease (AD), and Parkinson's disease (PD). The advancements in nanotechnology have paved the way for the development of nanocarrier systems that can target the underlying pathogenesis of these diseases. The study aimed to explore the efficacy of nanosystems in treating epilepsy, AD, and PD by analyzing relevant articles from databases such as Medline, PubMed and the national library of medicine. The review discusses the targeted delivery of active therapeutics to the central nervous system, with a focus on modulating neuronal and endothelial cell activity. It highlights various nanotherapeutic approaches, including pH-responsive nanomaterial-based therapeutics, nano-bioelectronic-implantable transient electronic devices, and electro-responsive nanosystems for the treatment of epilepsy. Additionally, the efficacy of nanodrug delivery systems loaded with curcumin, monoclonal anti-tau antibody-coated gold nanoparticles, Polyethylene Glycolpolylactide-Polyglycolide (PEG-PLGA) nanoparticles loaded with lactoferrin, dopamine-conjugated Albumin/PLGA nanosystems, and curcumin-loaded T807/RPCNP nanoparticles against neurodegeneration is discussed. The findings of this review provide valuable insights into the implications and challenges of nanotherapeutics in the field of neurological diseases. Neurologists and clinicians can benefit from this knowledge to better understand the potential applications of nanotherapeutics in the diagnosis and treatment of these conditions.

show abstract

Section: Parkinson's Disease (Pd)mentioning

confidence: 99%

Recent advances in nanotherapeutics for epilepsy and neurodegenerative diseases

Kuchik,

Doke,

Bhor

et al. 2023

JPBS

View full text Add to dashboard Cite

show abstract

“…An additional therapeutic candidate is the TFs family FoxO, which transactivate genes that control autophagosome biogenesis and the formation of the autolysosome. Regulation of FoxO activity constitute a promising therapeutic strategy in the fields of senescence and age-related diseases ( Calissi et al, 2021 ) which could potentially benefit the treatment of PD For instance, targeting the expression of the transcription factor FoxO6 ( Desai et al, 2020 ) and FoxO3 ( Pino et al, 2014 ) emerges as a promising alternative to regulate autophagy and prevent neurodegeneration by promoting the removal of misfolded, aggregated, toxic proteins ( Dumitriu et al, 2012 ; Santo and Paik, 2018 ). Overall, based on the preclinical studies, it is clear that approaches targeting gene expression can effectively treat PD.…”

Section: Targeting Gene Expressionmentioning

confidence: 99%

Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease

Sanchez-Mirasierra

Ghimire

Hernández-Díaz

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Macroautophagy, an evolutionary conserved catabolic process in the eukaryotic cell, regulates cellular homeostasis and plays a decisive role in self-engulfing proteins, protein aggregates, dysfunctional or damaged organelles, and invading pathogens. Growing evidence from in vivo and in vitro models shows that autophagy dysfunction plays decisive role in the pathogenesis of various neurodegenerative diseases, including Parkinson’s disease (PD). PD is an incurable and second most common neurodegenerative disease characterised by neurological and motor dysfunction accompanied of non-motor symptoms that can also reduce the life quality of patients. Despite the investment in research, the aetiology of the disease is still unknown and the therapies available are aimed mostly at ameliorating motor symptoms. Hence, therapeutics regulating the autophagy pathway might play an important role controlling the disease progression, reducing neuronal loss and even ameliorating non-motor symptoms. In this review, we highlight potential therapeutic opportunities involved in different targeting options like an initiation of autophagy, Leucine-rich repeat kinase 2 (LRRK2) inhibition, mitophagy, lysosomes, lipid metabolism, immune system, gene expression, biomarkers, and also non-pharmacological interventions. Thus, strategies to identify therapeutics targeting the pathways modulating autophagy might hold a future for therapy development against PD.

show abstract